We are live on ! Find out more
GS

Gilead Sciences Portfolio holdings

AUM $2.12B
1-Year Est. Return 143.53%
This Fund
S&P 500
This Quarter Est. Return
+38.77%
1 Year Est. Return
+143.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.79B
AUM Growth
+$511M
Cap. Flow
+$45.3M
Cap. Flow %
2.53%
Top 10 Hldgs %
100%
Holding
14
New
–
Increased
1
Reduced
–
Closed
5

Top Buys

Rank Stock Value
1
ASMB icon
Assembly Biosciences
ASMB
+$50.4M

Top Sells

Rank Stock Value
1
HOOK
HOOKIPA Pharma
HOOK
+$2.35M
2
ALLO icon
Allogene Therapeutics
ALLO
+$1.31M
3
KLRS
Kalaris Therapeutics
KLRS
+$848K
4
IMA
ImageneBio Inc
IMA
+$467K
5
BRNS
Barinthus Biotherapeutics
BRNS
+$92.5K

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$579M 32.31%
16,707,477
– –
ACLX
2
DELISTED
Arcellx
ACLX
$552M 30.8%
6,720,803
– –
RCUS icon
3
Arcus Biosciences
RCUS
$3.55B
$427M 23.86%
31,424,760
– –
ASMB icon
4
Assembly Biosciences
ASMB
$498M
$115M 6.44%
4,505,391
+2,295,920
+104% +$50.4M
MRUS
5
DELISTED
Merus
MRUS
$42.6M 2.38%
452,527
– –
TNGX icon
6
Tango Therapeutics
TNGX
$4.43B
$40.8M 2.28%
4,854,443
– –
KYTX icon
7
Kyverna Therapeutics
KYTX
$444M
$24.8M 1.38%
4,126,119
– –
XLO icon
8
Xilio Therapeutics
XLO
$59.9M
$7.67M 0.43%
650,389
– –
CYPH
9
Cypherpunk Technologies Inc
CYPH
$62.9M
$2.41M 0.13%
5,319,148
– –
ALLO icon
10
Allogene Therapeutics
ALLO
$649M
– –
-1,156,689
Closed -$1.31M
BRNS
11
Barinthus Biotherapeutics
BRNS
$22.8M
– –
-99,478
Closed -$92.5K
HOOK
12
DELISTED
HOOKIPA Pharma
HOOK
– –
-1,875,945
Closed -$2.35M
IMA
13
ImageneBio Inc
IMA
$63M
– –
-29,045
Closed -$467K
KLRS
14
Kalaris Therapeutics
KLRS
$83.5M
– –
-317,789
Closed -$848K

Similar funds

BCM
Basswood Capital Management New York $2.12B AUM 19.53% 1-Year Est. Return
IVAV
Index Venture Associates VI St. Helier, Channel Islands, Jersey $2.11B AUM 13.76% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
HJGA
Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return
CF
Centaurus Financial Anaheim, California $2.1B AUM 21.28% 1-Year Est. Return
BWC
Blue Whale Capital London, United Kingdom $2.1B AUM 97.03% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Gilead Sciences's Q3 2025 Portfolio in Review

As of Q3 2025, Gilead Sciences held 14 positions worth $1.79B, up 40% from $1.28B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Gilead Sciences's Q3 2025 filing shows 1 increased and 5 closed positions. The largest sale was HOOKIPA Pharma, an estimated $2.35M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Gilead Sciences added most to Assembly Biosciences in Q3 2025, an estimated $50.4M increase.
  • Gilead Sciences fully exited HOOKIPA Pharma in Q3 2025, selling an estimated $2.35M.
  • Gilead Sciences's ten largest holdings make up 100% of its $1.79B portfolio in Q3 2025.
  • Gilead Sciences opened 0 new positions and closed 5 in Q3 2025.
  • Gilead Sciences's portfolio value rose 40% quarter-over-quarter to $1.79B.

Based on Gilead Sciences's 13F filing for Q3 2025, filed 13 Nov 2025.